Apyx Medical Corp (APYX) research
Apyx Medical Corp- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $2.60
- As of
Kresmion compiles this page from APYX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Apyx Medical Corp (APYX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
As of . Source: SEC EDGAR filings for APYX. Method and limitations.
Share the APYX intelligence card
See the full APYX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for APYX on one page. Preview it with sample data, then open it live with a free account.
Preview the APYX dossierActive signals for APYX
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 16.3%, EPS $-0.07 vs $-0.0836 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1449% to APYX (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +83% to APYX (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 5.5% - EPS $-0.09 vs $-0.0952 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 52.2% - EPS $-0.05 vs $-0.1046 estimate
FREE, NO ACCOUNT
Every signal on APYX, as it fires
You are seeing 5 of 7 signals recorded on APYX since 2026-06-10.
The five above landed across 2 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in APYX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03837C106 · 2026Q2 | $2.5M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03837C106 · 2026Q2 | $1.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03837C106 · 2026Q2 | $756K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 03837C106 · 2026Q2 | $118K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, APYX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
APYX against its peers
APYX's operating margin of -12.2% ranks in the 81st percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | APYX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 52.8M USD | 32.0M USD | 65 | 23 |
| Gross margin | 62.5% | 50.2% | 61 | 18 |
| Operating margin | -12.2% | -55.8% | 81 | 23 |
| Net margin | -21.2% | -66.4% | 85 | 23 |
| Return on equity | -77.1% | -86.8% | 53 | 19 |
Peers (23): LUCD, HYPR, ECOR, LNSR, SERA, LUNG, OWLT, ZOMDF, OM, STIM, EBRCZ, MYO, QTRX, MDNC, POSC, MDAI, COCH, TELA, XTNT, NNOX, ELMD, SRTS, RPID. Left out: RTGN (no annual filing), PROF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (APYX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow APYX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to APYX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.